Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Rusconi

Showing results (91-100 of 192) with videos related to

Pageof 20
Sort By:
SAGE Open Medicine|June 15, 2018
Clinical and genetic determinants of nevirapine plasma trough concentrationAndrea Giacomelli, Stefano Rusconi, Felicia Stefania Falvella, et al.
AIDS Research and Human Retroviruses|September 13, 2022
Perceptions of U = U Among Italian Infectious Diseases Specialists: A Nationwide Survey on Providers' Attitudes Toward the Risk of HIV Transmission in Virologically Suppressed PatientsDiego Ripamonti, Mariacristina Poliseno, Giovanni Mazzola, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 20, 2016
Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical settingLetizia Marinaro, Andrea Calcagno, Diego Ripamonti, et al.
Brain : a Journal of Neurology|August 22, 2024
Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized studyAndrea Calcagno, Jessica Cusato, Paola Cinque, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|July 28, 2021
Correlation between continuous Positive end-expiratory pressure (PEEP) values and occurrence of Pneumothorax and Pneumomediastinum in SARS-CoV2 patients during non-invasive ventilation with HelmetAntonio Gidaro, Federica Samartin, Anna Maria Brambilla, et al.
Journal of Medical Virology|June 15, 2019
Impact of genotypic susceptibility score on cART outcomes during primary HIV infectionAndrea Giacomelli, Massimiliano Fabbiani, Ilaria De Benedetto, et al.
BMC Infectious Diseases|November 14, 2018
Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapyAndrea Giacomelli, Agostino Riva, Felicia Stefania Falvella, et al.
International Journal of Antimicrobial Agents|September 16, 2019
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patientsGianmaria Baldin, Arturo Ciccullo, Stefano Rusconi, et al.
HIV Medicine|December 2, 2024
Predictors for choosing doravirine-based versus INSTI-based regimen in ART-naïve and ART-experienced people with HIV in real-world setting: Data from the Icona cohortAntonella d'Arminio Monforte, Alessandro Tavelli, Eugenia Quiros-Roldan, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 19, 2012
The feature of Metabolic Syndrome in HIV naive patients is not the same of those treated: results from a prospective studyPaolo Bonfanti, Giuseppe Vittorio De Socio, Elena Ricci, et al.
Pageof 20

Showing results (91-100 of 192) with videos related to

Sort By:
Pageof 20
SAGE Open Medicine|June 15, 2018
Clinical and genetic determinants of nevirapine plasma trough concentrationAndrea Giacomelli, Stefano Rusconi, Felicia Stefania Falvella, et al.
AIDS Research and Human Retroviruses|September 13, 2022
Perceptions of U = U Among Italian Infectious Diseases Specialists: A Nationwide Survey on Providers' Attitudes Toward the Risk of HIV Transmission in Virologically Suppressed PatientsDiego Ripamonti, Mariacristina Poliseno, Giovanni Mazzola, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 20, 2016
Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical settingLetizia Marinaro, Andrea Calcagno, Diego Ripamonti, et al.
Brain : a Journal of Neurology|August 22, 2024
Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized studyAndrea Calcagno, Jessica Cusato, Paola Cinque, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|July 28, 2021
Correlation between continuous Positive end-expiratory pressure (PEEP) values and occurrence of Pneumothorax and Pneumomediastinum in SARS-CoV2 patients during non-invasive ventilation with HelmetAntonio Gidaro, Federica Samartin, Anna Maria Brambilla, et al.
Journal of Medical Virology|June 15, 2019
Impact of genotypic susceptibility score on cART outcomes during primary HIV infectionAndrea Giacomelli, Massimiliano Fabbiani, Ilaria De Benedetto, et al.
BMC Infectious Diseases|November 14, 2018
Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapyAndrea Giacomelli, Agostino Riva, Felicia Stefania Falvella, et al.
International Journal of Antimicrobial Agents|September 16, 2019
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patientsGianmaria Baldin, Arturo Ciccullo, Stefano Rusconi, et al.
HIV Medicine|December 2, 2024
Predictors for choosing doravirine-based versus INSTI-based regimen in ART-naïve and ART-experienced people with HIV in real-world setting: Data from the Icona cohortAntonella d'Arminio Monforte, Alessandro Tavelli, Eugenia Quiros-Roldan, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 19, 2012
The feature of Metabolic Syndrome in HIV naive patients is not the same of those treated: results from a prospective studyPaolo Bonfanti, Giuseppe Vittorio De Socio, Elena Ricci, et al.
Pageof 20